NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Post-Partum Immunization With Live Attenuated Influenza Vaccine (LAIV) or Trivalent Influenza Vaccine (TIV) in Post-Partum Breast Feeding Women

Phase 2

Completed

Conditions: Influenza

Interventions: Biological: Cold-adapted live attenuated influenza virus vaccine, trivalent
Other: Placebo
Biological: Trivalent inactivated influenza vaccine

First Posted Date: 2010-08-13

Last Posted Date: 2015-01-28

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 240

Registration Number: NCT01181323

Locations: 🇺🇸
Emory Children's Center - Pediatric Infectious Diseases, Atlanta, Georgia, United States
🇺🇸
Group Health Research Institute - Seattle, Seattle, Washington, United States
🇺🇸
Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States

and more 3 locations

Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 Influenza

Phase 1

Completed

Conditions: Influenza A Virus Infection

Interventions: Biological: H2N3 MO 2003/AA ca Vaccine

First Posted Date: 2010-08-04

Last Posted Date: 2013-02-11

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 20

Registration Number: NCT01175122

Locations: 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States

Influenza Antiviral DAS181-F03

Phase 1

Completed

Conditions: Influenza

Interventions: Drug: Placebo
Drug: DAS181

First Posted Date: 2010-07-30

Last Posted Date: 2013-07-19

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 18

Registration Number: NCT01173224

Locations: 🇺🇸
Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States

2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women

Phase 2

Completed

Conditions: Influenza

Interventions: Biological: Trivalent inactivated influenza vaccine

First Posted Date: 2010-07-30

Last Posted Date: 2014-12-24

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 183

Registration Number: NCT01173211

Locations: 🇺🇸
Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States
🇺🇸
Duke University Medical Center - Duke Perinatal Clinic, Durham, North Carolina, United States
🇺🇸
Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center, Nashville, Tennessee, United States

and more 2 locations

A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines

Phase 2

Completed

Conditions: HIV

Interventions: Drug: Lopinavir/ritonavir

First Posted Date: 2010-07-29

Last Posted Date: 2021-11-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 97

Registration Number: NCT01172535

Locations: 🇺🇸
University of California, UC San Diego CRS, La Jolla, California, United States
🇺🇸
Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States
🇧🇷
Hosp. Santa Casa Porto Alegre Brazil NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil

and more 16 locations

Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early Childhood in Ouelessebougou and Bamako, Mali

Recruiting

Conditions: Malaria

First Posted Date: 2010-07-23

Last Posted Date: 2025-05-28

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 15000

Registration Number: NCT01168271

Locations: 🇲🇱
Gabriel Toure Hospital, Bamako, Mali
🇲🇱
Ouelessebougou Clinical Research Center, Ouelessebougou, Mali

EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum Malaria

Phase 1

Completed

Conditions: Plasmodium Falciparum Malaria

Interventions: Drug: Placebo
Biological: EP-1300

First Posted Date: 2010-07-23

Last Posted Date: 2012-11-16

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 39

Registration Number: NCT01169077

Locations: 🇺🇸
Emory Children's Center - Pediatric Infectious Diseases, Atlanta, Georgia, United States

Evaluating the Safety of ITX 5061 in Treatment-Naive Hepatitis C (HCV)-Infected Adults

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: ITX 5061
Drug: Placebo ITX 5061

First Posted Date: 2010-07-19

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 30

Registration Number: NCT01165359

Locations: 🇺🇸
Alabama Therapeutics CRS, Birmingham, Alabama, United States
🇺🇸
Ucsd, Avrc Crs, San Diego, California, United States
🇺🇸
Univ. of Cincinnati CRS, Cincinnati, Ohio, United States

and more 7 locations

Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram-negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant

Phase 1

Terminated

Conditions: Bacterial Sepsis

Interventions: Biological: J5-OMP Vaccine
Biological: CPG 7909
Drug: Placebo

First Posted Date: 2010-07-16

Last Posted Date: 2014-01-31

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 20

Registration Number: NCT01164514

Locations: 🇺🇸
University of Maryland Medical System - General Clinical Research Center (GCRC), Baltimore, Maryland, United States

Comparison of Flu Vaccine Doses in Children

Phase 1

Completed

Conditions: Influenza

Interventions: Biological: Trivalent Inactivated Influenza Vaccine

First Posted Date: 2010-07-16

Last Posted Date: 2013-04-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 243

Registration Number: NCT01164553

Locations: 🇺🇸
Emory University School of Medicine - Emory Children's Center - Pediatric Infectious Diseases, Atlanta, Georgia, United States
🇺🇸
Emory Children's Center - Pediatric Infectious Diseases, Atlanta, Georgia, United States
🇺🇸
Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy